Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? [Yahoo! Finance]
Olema Pharmaceuticals, Inc. (OLMA)
Company Research
Source: Yahoo! Finance
What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Paradigm Biocapital Advisors increased its holdings in Olema Pharmaceuticals by 750,000 shares during the fourth quarter of 2025. The quarter-end value of the Olema Pharmaceuticals stake stood at $122.09 million. What else to know This was a net buy, raising the position to some 4.5% of Paradigm's reportable AUM as of December 31, 2025. Top holdings after the filing: NASDAQ:NUVL: $530.05 million (14.2% of AUM) NASDAQ:RVMD: $529.23 million (14.2% of AUM) NASDAQ:ACLX: $373.21 million (10.0% of AUM) NASDAQ:GMAB: $216.83 million (5.8% of AUM) NASDAQ:TARS: $209.79 million (5.6% of AUM) As of February 17, 2026, Olema Pharmaceuticals shares were priced at $14.08, up a staggering 242% over the past year and significantly outperforming the S&P 500's roughly 15% gain in the same period. Company overview Metric Value Price (as of Friday) Market capitalization $1.
Show less
Read more
Impact Snapshot
Event Time:
OLMA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OLMA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OLMA alerts
High impacting Olema Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OLMA
News
- Jim Cramer on Olema Pharmaceuticals: “Too Risky for Me” [Yahoo! Finance]Yahoo! Finance
- Olema Shelf Registration Raises Questions On Dilution And Funding Flexibility [Yahoo! Finance]Yahoo! Finance
- Olema Pharmaceuticals (OLMA) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.MarketBeat
- Olema Pharmaceuticals (OLMA) had its price target raised by JPMorgan Chase & Co. from $55.00 to $58.00. They now have an "overweight" rating on the stock.MarketBeat
- Olema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]Yahoo! Finance
OLMA
Earnings
- 3/16/26 - Beat
OLMA
Sec Filings
- 3/20/26 - Form SCHEDULE
- 3/16/26 - Form 144
- 3/16/26 - Form 144
- OLMA's page on the SEC website